These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 18508192)

  • 21. PTHrP stimulates prostate cancer cell growth and upregulates aldo-keto reductase 1C3.
    Downs TM; Burton DW; Araiza FL; Hastings RH; Deftos LJ
    Cancer Lett; 2011 Jul; 306(1):52-9. PubMed ID: 21444150
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Human type 3 3alpha-hydroxysteroid dehydrogenase (aldo-keto reductase 1C2) and androgen metabolism in prostate cells.
    Rizner TL; Lin HK; Peehl DM; Steckelbroeck S; Bauman DR; Penning TM
    Endocrinology; 2003 Jul; 144(7):2922-32. PubMed ID: 12810547
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibitors of type 5 17β-hydroxysteroid dehydrogenase (AKR1C3): overview and structural insights.
    Byrns MC; Jin Y; Penning TM
    J Steroid Biochem Mol Biol; 2011 May; 125(1-2):95-104. PubMed ID: 21087665
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Two pathways for prostaglandin F2 alpha synthesis by the primate periovulatory follicle.
    Dozier BL; Watanabe K; Duffy DM
    Reproduction; 2008 Jul; 136(1):53-63. PubMed ID: 18390687
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of PI3K and calcineurin suppresses chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2)-dependent responses of Th2 lymphocytes to prostaglandin D(2).
    Xue L; Gyles SL; Barrow A; Pettipher R
    Biochem Pharmacol; 2007 Mar; 73(6):843-53. PubMed ID: 17196174
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Steroidogenic Enzyme AKR1C3 Regulates Stability of the Ubiquitin Ligase Siah2 in Prostate Cancer Cells.
    Fan L; Peng G; Hussain A; Fazli L; Guns E; Gleave M; Qi J
    J Biol Chem; 2015 Aug; 290(34):20865-20879. PubMed ID: 26160177
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of a monoclonal antibody for human aldo-keto reductase AKR1C3 (type 2 3alpha-hydroxysteroid dehydrogenase/type 5 17beta-hydroxysteroid dehydrogenase); immunohistochemical detection in breast and prostate.
    Lin HK; Steckelbroeck S; Fung KM; Jones AN; Penning TM
    Steroids; 2004 Dec; 69(13-14):795-801. PubMed ID: 15582534
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An indomethacin analogue, N-(4-chlorobenzoyl)-melatonin, is a selective inhibitor of aldo-keto reductase 1C3 (type 2 3alpha-HSD, type 5 17beta-HSD, and prostaglandin F synthase), a potential target for the treatment of hormone dependent and hormone independent malignancies.
    Byrns MC; Steckelbroeck S; Penning TM
    Biochem Pharmacol; 2008 Jan; 75(2):484-93. PubMed ID: 17950253
    [TBL] [Abstract][Full Text] [Related]  

  • 29. AKR1C3 as a target in castrate resistant prostate cancer.
    Adeniji AO; Chen M; Penning TM
    J Steroid Biochem Mol Biol; 2013 Sep; 137():136-49. PubMed ID: 23748150
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development of potent and selective inhibitors of aldo-keto reductase 1C3 (type 5 17β-hydroxysteroid dehydrogenase) based on N-phenyl-aminobenzoates and their structure-activity relationships.
    Adeniji AO; Twenter BM; Byrns MC; Jin Y; Chen M; Winkler JD; Penning TM
    J Med Chem; 2012 Mar; 55(5):2311-23. PubMed ID: 22263837
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of AKR1C3 Activation Overcomes Resistance to Abiraterone in Advanced Prostate Cancer.
    Liu C; Armstrong CM; Lou W; Lombard A; Evans CP; Gao AC
    Mol Cancer Ther; 2017 Jan; 16(1):35-44. PubMed ID: 27794047
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term androgen-ablation causes increased resistance to PI3K/Akt pathway inhibition in prostate cancer cells.
    Pfeil K; Eder IE; Putz T; Ramoner R; Culig Z; Ueberall F; Bartsch G; Klocker H
    Prostate; 2004 Feb; 58(3):259-68. PubMed ID: 14743465
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impaired dihydrotestosterone catabolism in human prostate cancer: critical role of AKR1C2 as a pre-receptor regulator of androgen receptor signaling.
    Ji Q; Chang L; Stanczyk FZ; Ookhtens M; Sherrod A; Stolz A
    Cancer Res; 2007 Feb; 67(3):1361-9. PubMed ID: 17283174
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of potent and selective indomethacin analogues for the inhibition of AKR1C3 (Type 5 17β-hydroxysteroid dehydrogenase/prostaglandin F synthase) in castrate-resistant prostate cancer.
    Liedtke AJ; Adeniji AO; Chen M; Byrns MC; Jin Y; Christianson DW; Marnett LJ; Penning TM
    J Med Chem; 2013 Mar; 56(6):2429-46. PubMed ID: 23432095
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aldo-keto reductase 1C3 is expressed in differentiated human epidermis, affects keratinocyte differentiation, and is upregulated in atopic dermatitis.
    Mantel A; Carpenter-Mendini AB; Vanbuskirk JB; De Benedetto A; Beck LA; Pentland AP
    J Invest Dermatol; 2012 Apr; 132(4):1103-10. PubMed ID: 22170488
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Progestin effects on expression of AKR1C1-AKR1C3, SRD5A1 and PGR in the Z-12 endometriotic epithelial cell line.
    Beranič N; Lanišnik Rižner T
    Chem Biol Interact; 2013 Feb; 202(1-3):218-25. PubMed ID: 23183084
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interleukin-6 regulates androgen synthesis in prostate cancer cells.
    Chun JY; Nadiminty N; Dutt S; Lou W; Yang JC; Kung HJ; Evans CP; Gao AC
    Clin Cancer Res; 2009 Aug; 15(15):4815-22. PubMed ID: 19638459
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer.
    Stanbrough M; Bubley GJ; Ross K; Golub TR; Rubin MA; Penning TM; Febbo PG; Balk SP
    Cancer Res; 2006 Mar; 66(5):2815-25. PubMed ID: 16510604
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Modulated expression of genes encoding estrogen metabolizing enzymes by G1-phase cyclin-dependent kinases 6 and 4 in human breast cancer cells.
    Jia Y; Domenico J; Swasey C; Wang M; Gelfand EW; Lucas JJ
    PLoS One; 2014; 9(5):e97448. PubMed ID: 24848372
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Aldo-keto reductase family 1 member C3 (AKR1C3) is a biomarker and therapeutic target for castration-resistant prostate cancer.
    Hamid AR; Pfeiffer MJ; Verhaegh GW; Schaafsma E; Brandt A; Sweep FC; Sedelaar JP; Schalken JA
    Mol Med; 2013 Jan; 18(1):1449-55. PubMed ID: 23196782
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.